Vesta vs Visiopharm
Valar raised a $22 million Series A on May 22, 2024, co-led by DCVC and a16z. What it sells is an AI read of bladder cancer slides: BCGPredict for BCG response, and Risk Stratify for recurrence and progression scores. The ordering physician is a urologist at a practice treating non-muscle-invasive bladder cancer (NMIBC) patients. An openFDA 510(k) query on November 2, 2026 under the applicant name Valar and the device name Vesta returns no Valar Labs record.
Visiopharm, founded in Denmark in 2002, says it sells CE-IVD apps under IVDR for ER, PR, HER2 and Ki-67, and its homepage lists breast, lung and prostate cancer. The vendor says at least nine diagnostic algorithms are cleared under IVDR for EU and UK customers, and it also sells a research-use platform to pharma and academia. An openFDA search under the applicant name visiopharm on October 14, 2026 returned no match. Grundium Oy announced its acquisition on May 21, 2026, terms undisclosed. Visiopharm's buyer is a pathology lab licensing software and Valar's is the urologist ordering a test, and neither purchase substitutes for the other.
Pathology · Reviewed November 2, 2026
Vesta
by Valar Labs
Lab test run in a CLIA lab: AI on routine bladder cancer slides predicts BCG response, ordered by urologists.
Visiopharm
by Visiopharm
Pathology image-analysis software with CE-IVD apps for breast, lung and prostate biomarkers and a research-use platform.
When to pick each one
Vesta
- Vesta Bladder risk scores and BCG response test
- $22M Series A from DCVC and a16z
Visiopharm
- CE-IVD apps for ER, PR, HER2 and Ki-67
- RUO image-analysis platform for pharma and academia
- Pairs with a Grundium scanner, per the homepage
Score
Each row shows points earned of points available under the published rubric.
Vesta
16of 100
Visiopharm
43of 100
| Dimension | Vesta | Visiopharm | Difference |
|---|---|---|---|
| FDA clearance | 0 / 18 | 0 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 8.4 / 21 | 21 / 21 | -12.6 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 7.8 / 7.8 | -7.8 |
| Funding & adoption signal | 3 / 12 | 6 / 12 | -3 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 0 / 6 | 0 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
Vesta
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Visiopharm
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Evidence
Vesta
FDA decisions
No FDA decision cited in our research as of November 2, 2026.
Peer-reviewed
1 PubMed record names Vesta.
Visiopharm
FDA decisions
No FDA decision cited in our research as of October 20, 2026.
Peer-reviewed
5 PubMed records name Visiopharm.
- Inter-rater agreement of HER2-low scores between expert breast pathologists and the Visiopharm digital image analysis application (HER2 APP, CE2797). (opens in new tab)
- Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: the CONFIDENT-B single-center, non-randomized clinical trial. (opens in new tab)
- Head-to-Head Comparison of 2 Artificial Intelligence Tools for Detecting Lymph Node Metastases in Whole-Slide Pathology Images Within and Beyond Their Intended Use. (opens in new tab)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Vesta | Visiopharm |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | n/a | n/a |
| HQ | n/a | DK |
Scroll horizontally to see both columns.
Common questions
Open the full pathology comparison
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.